# Romosozumab-Aqqg (Evenity)

Source: https://ourhealthnetwork.com/drugs/romosozumab-aqqg
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Romosozumab-Aqqg?

Romosozumab-Aqqg (brand name: Evenity) is a monoclonal antibodies. It is prescribed to treat osteoporosis, postmenopausal. Across the United States, 702 doctors prescribe Romosozumab-Aqqg to approximately 2,000 Medicare patients.

## Brand names

Evenity

## Indications

Romosozumab-Aqqg is prescribed for the treatment of osteoporosis and postmenopausal.

## Conditions treated

- [Osteoporosis](https://ourhealthnetwork.com/conditions/osteoporosis)
- [Postmenopausal](https://ourhealthnetwork.com/conditions/postmenopausal)

## Mechanism of action

EVENITY inhibits the action of sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption.

## Drug classification

- Established Pharmacologic Class: monoclonal antibodies
- Route of administration: SUBCUTANEOUS

## Common side effects

arthralgia, headache

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)